Replimune Group raises target price to $27 from $14
REPL•Piper Sandler raised its target price for Replimune Group to $27 from $14.
Related News

Consolidated Edison: BofA Global Research raises price objective to $106.00 from $96.00
ED•

Actuate Therapeutics, Inc.: H.C. Wainwright cuts target price to $10 from $15
ACTU•

Wells Fargo raises Healthcare Realty Trust target price to $19 from $18
HR•

electroCore director Thomas J. Errico reports acquisition of $54,400 in common shares
ECOR•

Pixelworks board doubles stock repurchase authorization to $10 million
PXLW•